Navigenics, which plans to offer individuals a personalized genetic analysis so they can better manage their health, "launched" its service -- sort of -- and announced that it has raised more than $25 million.
As we point out at VentureBeat Life Sciences, however, the company's launch is really just a promise to begin its service early next year, at a price of $2,500 per person. Navigenics also lined up Mohr Davidow Ventures -- an early backer of potential competitor 23andMe -- as a new investor, and we're also told that Google, which has both personal and financial ties to 23andMe, has quietly invested in Navigenics as well.